Table of Contents
Research & Development
| Roche Signs US$2.8 B Deal with Alnylam to Develop RNAi Therapeutic for Hypertension | Abstract pdf html |
| Amit Kaushik |
| Astellas Enters into Collaborations with PeptiDream and Cullgen to Advance Targeted Protein Degraders | Abstract pdf html |
| Ashish Tripathi |
Licensing
| Agios signs US$147.5 M License Deal with Alnylam’s RNAi therapeutic for Polycythemia Vera | Abstract pdf html |
| Shweta Gupta |
Mergers & Acquisitions
| Biogen to Acquire Reata for US$7.3 B for Rare Disease Portfolio | Abstract pdf html |
| Lalit Mishra |
This work is licensed under a Creative Commons Attribution 3.0 License.